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Introduction to Mitochondrial Genome
M itochondria are the organelles universally known asthe cellular power plants because they generate most
of the cellular energy by oxidative phosphorylation. Moreover,
mitochondria are involved in many other cellular activities,
such as hormones and heme synthesis, calcium ions storage,
and regulation of cellular proliferation and/or differentiation.1
The role of mitochondrial dysfunction in cardiovascular
pathophysiology, and in particular in myocardial infarction,
cardiac hypertrophy, and heart failure has been extensively
evaluated.2,3
Mitochondria are also the only extranuclear compartment
that contains genetic material in form of deoxyribonucleic
acid (DNA), probably as the result of an endosymbiotic event
between ancestral eukaryotic cells and aerobic bacteria in the
early evolutionary stage of eukaryotes.1 Each cell contains
hundreds to thousands of copies of the mitochondrial DNA
(mtDNA) genome, which has a maternal inheritance. Human
mtDNA is a closed circular double-stranded DNA with 16 569
base pairs (bp) encoding 37 genes: 13 for the essential
subunits of respiratory complexes I, III, IV, and V; 22 for
mitochondrial transport-RNAs (mt-tRNAs); and 2 for ribo-
somal-RNAs (mt-rRNAs).1 All the RNA components necessary
for mitochondrial translation are supplied in mitochondria,
whereas all protein components are encoded by nuclear DNA
and transported into the mitochondria after their cytoplasmic
synthesis.1
The biochemical processes in mitochondria occur at much
faster rates than those in the host cell. The rapidity of
mtDNA replication machinery, however, is not without
consequences, particularly due to the presence of reactive
oxygen species (ROS) in mitochondria environment. Of
consequence, mtDNA is more prone to accumulate mutations
with a 16 times higher mutation accumulation rate than the
nuclear DNA.4 Mutations could initiate a cyclic process in
which impaired mitochondrial functions and increased ROS
cause a higher error rates of DNA polymerases with further
accumulation of mutated mtDNA.4 Mutations in mtDNA have
been linked to various maternal inherited human diseases.1,4
A large number of mutations in mt-tRNA genes have been
mapped to mt-tRNAs locus, and approximately half of
mitochondrial disease is caused by mutations involving these
genes (Table).1 Mutations in an mt-tRNA gene may negatively
influence biogenesis and functioning of tRNAs after their
transcription, including processing, post-transcriptional mod-
ification, aminoacylation, association with mitochondrial elon-
gation factors, and/or interactions with the mitoribosome
during translation.1 Mutations rarely provoke critical struc-
tural and/or functional alterations of tRNAs, because they
generally result in a severe phenotype that is likely to be
incompatible with embryogenesis and development.1 The
coexistence of a mixture of molecules of mutated and wild
type mtDNA within mitochondria is called heteroplasmy and
the percentage of mutated, pathologic DNA is a key factor for
the severity of disease; on the contrary the presence of all
identical copies of mtDNA, wild type or pathologic, is known
as homoplasmy.
mt-tRNAs and Coronary Artery Disease
Only a few studies have evaluated the potential role of mt-
tRNAs mutations and coronary artery disease (CAD). Jia et al
were the first to assess a correlation between specific point
mutations of mt-tRNA genes and CAD5 by studying a 4-
generation Chinese Han family with 13 of 32 members affected
by maternally inherited CAD. They identified the G>A mutation
at site 15927 of tRNA-Thr gene, which resulted in decreased
aminoacylated efficiency of tRNA-Thr, with a 53% reduction
rate of mitochondrial translation in mutant cells.5 The impaired
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mitochondrial protein synthesis leads to defects in overall
respiratory capacity, malate/glutamate-promoted respiration,
succinate/glycerol-3-phosphate promoted respiration, and N,
N,N0,N0-tetramethyl-pphenylenediamine/ascorbate-promoted
respiration in immortalized lymphoblasts from subjects
carrying the mutation with a concomitant increase in ROS
production.5
In the present issue of JAHA, Qin et al investigated a total
of 80 genetically unrelated Chinese subjects with coronary
heart disease, whose ages were from 33 to 79 years old, and
identified tRNA-Gln 5592 T>C and the previously cited tRNA-
Thr 15927 G>A to be associated with a maternally inherited
form of CAD.6 tRNA-Gln 5592 A>G mutation is expected to
lead to decreased stability of tRNA and, as a consequence, to
a failure in tRNA metabolism, while tRNA-Thr 15927 G>A is
suggested to reduce steady-state level of tRNA.6 Such
alterations, again, are supposed to impair mitochondrial
translation, respiration and, in tandem, increase ROS gener-
ation.6 Data from a mutation analysis performed to assess
contribution of mtDNA variants or haplogroups toward the
phenotypic expression of these mtDNA mutations in these
Chinese pedigrees suggest that the cytochrome C oxidase
subunit 1 (CO1) G6969A (I356V) variant may have a role in
the phenotypic manifestation of tRNA-Thr 15927 G>A muta-
tion.6 The genetic evidence presented by Qin et al clearly
demonstrated that the identified mt-tRNA mutations, even if
not present in homoplasmic state, represent an inherited risk
factor for CAD. Therefore, these findings might significantly
impact the understanding of the different roles of mt-tRNAs in
cardiovascular pathophysiology.
mt-tRNAs and Cardiomyopathies
The 2 most significant examples of mt-tRNA-related cardio-
myopathies are represented by MELAS (mitochondrial en-
cephalomyopathy, lactic acidosis, and stroke-like episodes), a
major and well characterized mitochondrial disease caused by
point mutations in mt-tRNA-Leu (UUR) genes, and MERRF
(myoclonic epilepsy with ragged red fibers), a major subgroup
of the mitochondrial encephalomyopathies caused by a point
mutation at position 8344 in the mt-tRNALys gene.1 These
diseases are also characterized by variable cardiac involve-
ment including hypertrophic cardiomyopathy, ventricular
systolic dysfunction, and Wolff-Parkinson-White syndrome.7
On the other hand, various types of isolated hypertrophic
cardiomyopathy (HCM) have also been described.8,9 Muta-
tions in mt-tRNA genes have been associated to HCM in about
the 10% of cases.8 Dilated cardiomyopathy associated with
mt-tRNA point mutations is less common than the hypertro-
phic phenotype.8 Pathophysiology of myocardial involvement
in mt-tRNA diseases is complex and probably related to
multiple factors, such as a compensatory mechanism(s) to a
deficient oxidative phosphorylation.8 Even if such diseases
generally comply with the “classic” scheme of monogenic
inheritance, their penetrance may be modified by other
factors such as the activity of specific tRNA synthetases.8
Table. mt-tRNAs Most Frequent Mutations Involved in
Cardiovascular Disease
Site Sostitution tRNA Phenotype
586 G>A Phe CKD
593 C>T Phe AH
3243 A>G Leu MELAS, diabetes, AH,
preeclampsia, HCM, DCM
3254 C>T Leu AH
3256 C>T Leu Atherosclerosis
3260 A>G Leu Heart failure, HCM
3264 T>C Leu Diabetes
3302 A>G Leu Rhythm disorders,
cardiorespiratory failure
3303 C>T Leu HCM
4263 A>G Lys AH
4269 A>G Ile HCM, DCM
4277 T>C Ile HCM
4291 T>C Ile AH, dyslipemia,
hypomagnesemia
4295 A>G Ile HCM, AH
4295 A>G Ile AH
4300 A>G Ile HCM
4317 A>G Ile HCM, DCM
4353 T>C Met AH
4401 A>G Met, Gln (50) AH
4435 A>G Met AH
4454 T>C Met AH
4454 T>C Met AH
5553 C>T Trp AH
5592 T>C Gln CAD
5814 T>C Cys AH
8344 A>G Lys MERRF, HCM
8348 A>G Lys AH
8363 G>A Lys HCM
9997 T>C Gly DCM,
12315 G>A Leu Atherosclerosis
15927 G>A Thr CAD
15928 G>A Thr AH
AH indicates arterial hypertension; CAD, coronary artery disease; CKD, chronic kidney
disease; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; MELAS,
mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; MERRF,
myoclonic epilepsy with ragged red fibers.
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mt-tRNAs and Arterial Hypertension
Mitochondrial genomic alterations have also been linked to
multifactorial cardiovascular disease, such as arterial hyper-
tension. Zhang et al have previously shown that a nucleotide
mutation in Leu mt-tRNA gene decreased cytochrome C
oxidase activity and led to mitochondrial and placental
dysfunction in preeclampsia.10 Schwartz et al identified
mutations in mt-tRNA genes in 14 of 20 hypertensive
subjects screened for mutations in mitochondrial genome,
some of which have previously been associated with HCM.11
Interestingly, the association between mt-tRNA genetic
pedigree and hypertensive phenotype has been extensively
investigated only in Chinese populations.12–14 Pathogenic
mechanisms of mt-tRNA mediated form of essential hyper-
tension probably involve ROS production, impaired ATP
production, modification in cytosolic calcium handling and,
possibly, apoptotic cell death. Other mutations at the same
promoter of tRNAIle gene have also been linked to a
maternally inherited form of hypertension, dyslipidaemia,
and hypomagnesaemia15 and to diabetes mellitus.16
Conclusive Remarks
Studies on mitochondrial genomic mutations and cardiovas-
cular diseases are a recent, fascinating field of research. While
mitochondriopathies are usually considered to cause severe
multi-organ involvement and rare diseases, it is crucial to note
that also for common diseases such as hypertension, meta-
bolic syndrome and CAD, several mutations may not have a
disease-causative role, but may predispose and determine the
genetic susceptibility to these diseases. mt-tRNAs abnormali-
ties may lead to various degree of mitochondrial dysfunction
that could be reflected in different phenotypic presentations of
disease. One of the major limits of all these studies regards the
paucity of data on the pathogenic mechanisms activated by
mt-tRNAs mutations. Moreover, the complexity of mt-tRNAs
genetic analysis, and the difficulties of experimental manipu-
lation of mtDNA sequences represent additional technical
issues in these studies. However, the evidence that mt-tRNA
mutations impair the efficiency of mitochondrial translation
machinery, worsen oxidative phosphorylation and fatty acid
metabolism and increase ROS production, further highlight the
well-known role of mitochondrial dysfunction in cardiovascular
pathophysiology.2,3
The study from Qin and coworkers, published on this issue
of JAHA, describes a correlation between mt-tRNA mutations
and maternal inheritance of CAD.6 Therefore, results of this
study may lay the ground for further studies evaluating the
role of mt-tRNA genetic instability on larger populations,
preferably of different ethnicity. The goal of future studies will
be to assess the role of mt-tRNAs mutations in the complex,
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